• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

SIGLEC1 在非小细胞肺癌中的失调：预后意义和免疫调节作用——一项多中心队列研究。

Dysregulation of SIGLEC1 in non-small cell lung cancer: prognostic implications and immunomodulatory role-a multicenter cohort study.

机构信息

Cancer Research Center Nantong, Affiliated Tumor Hospital of Nantong University, Nantong, 226006, China.

Department of Neuroscience, Shanghai Key Laboratory of Emotions and Affective Disorders, Songjiang Hospital and Songjiang Research Institute, Shanghai Jiao Tong University School of Medicine, Shanghai, 201600, China.

出版信息

J Cancer Res Clin Oncol. 2024 Oct 29;150(10):481. doi: 10.1007/s00432-024-06005-9.

DOI:10.1007/s00432-024-06005-9
PMID:39470815
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11522155/
Abstract

PURPOSE

To investigate the clinical significance and functional role of SIGLEC1-positive cells in non-small cell lungcancer (NSCLC) patients, focusing on their prognostic impact and therapeutic response.

METHODS

A multicenter retrospective cohort analysis was conducted, integrating data from multiple sources. Weanalyzed SIGLEC1 expression in NSCLC tissues, clinicopathological features, overall survival outcomes,chemotherapy responsiveness, and sensitivity to targeted therapies. We also developed a prognostic model basedon SIGLEC1 expression and clinical variables.

RESULTS

SIGLEC1 expression was significantly downregulated in NSCLC tissues, and the density of SIGLEC1-positivecells was inversely correlated with various clinicopathological features. Notably, patients with high infiltration ofSIGLEC1-positive cells exhibited significantly better overall survival outcomes. Furthermore, elevated SIGLEC1expression was associated with improved responsiveness to chemotherapy and demonstrated distinct patterns ofsensitivity to targeted therapies. A robust prognostic model was developed by integrating SIGLEC1 expression andclinical variables.

CONCLUSIONS

This study highlighted the downregulation of SIGLEC1 in NSCLC tissues and its significant associationwith patient prognosis and therapeutic response. The findings suggested that SIGLEC1 played a critical role inmodulating the tumor immune microenvironment and has potential as both a prognostic biomarker and therapeutictarget in NSCLC.

摘要

目的

研究 Siglec1 阳性细胞在非小细胞肺癌（NSCLC）患者中的临床意义和功能作用，重点关注其预后影响和治疗反应。

方法

进行了一项多中心回顾性队列分析，整合了来自多个来源的数据。我们分析了 NSCLC 组织中的 Siglec1 表达、临床病理特征、总生存结局、化疗反应性以及对靶向治疗的敏感性。我们还基于 Siglec1 表达和临床变量开发了一个预后模型。

结果

Siglec1 在 NSCLC 组织中表达明显下调，Siglec1 阳性细胞的密度与各种临床病理特征呈负相关。值得注意的是，Siglec1 阳性细胞浸润程度高的患者总生存结局显著改善。此外，Siglec1 的高表达与对化疗的反应性提高相关，并表现出对靶向治疗的明显敏感性模式。通过整合 Siglec1 表达和临床变量，建立了一个强大的预后模型。

结论

本研究强调了 Siglec1 在 NSCLC 组织中的下调及其与患者预后和治疗反应的显著关联。研究结果表明，Siglec1 在调节肿瘤免疫微环境中发挥着关键作用，具有作为 NSCLC 预后生物标志物和治疗靶点的潜力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9ad/11793553/19cce4eae96c/432_2024_6005_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9ad/11793553/68aeec7f75b2/432_2024_6005_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9ad/11793553/98de807b6e27/432_2024_6005_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9ad/11793553/a7a7d9195874/432_2024_6005_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9ad/11793553/77d5de2799e7/432_2024_6005_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9ad/11793553/30d593b68b93/432_2024_6005_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9ad/11793553/6232d7d71ffe/432_2024_6005_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9ad/11793553/7b7a9d512424/432_2024_6005_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9ad/11793553/19cce4eae96c/432_2024_6005_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9ad/11793553/68aeec7f75b2/432_2024_6005_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9ad/11793553/98de807b6e27/432_2024_6005_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9ad/11793553/a7a7d9195874/432_2024_6005_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9ad/11793553/77d5de2799e7/432_2024_6005_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9ad/11793553/30d593b68b93/432_2024_6005_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9ad/11793553/6232d7d71ffe/432_2024_6005_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9ad/11793553/7b7a9d512424/432_2024_6005_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a9ad/11793553/19cce4eae96c/432_2024_6005_Fig8_HTML.jpg

相似文献

1
Dysregulation of SIGLEC1 in non-small cell lung cancer: prognostic implications and immunomodulatory role-a multicenter cohort study.SIGLEC1 在非小细胞肺癌中的失调：预后意义和免疫调节作用——一项多中心队列研究。
J Cancer Res Clin Oncol. 2024 Oct 29;150(10):481. doi: 10.1007/s00432-024-06005-9.
2
[CD45RO⁺ Memory T Lymphocytes As A Candidate Marker for Non-small Cell Lung Cancer].[CD45RO⁺记忆性T淋巴细胞作为非小细胞肺癌的候选标志物]
Zhongguo Fei Ai Za Zhi. 2021 Apr 20;24(4):254-264. doi: 10.3779/j.issn.1009-3419.2021.103.05.
3
Low-exhaustion peripheral circulating γδ T cells serve as a biomarker for predicting the clinical benefit rate of non-small cell lung cancer (NSCLC) patients to chemotherapy or targeted therapy: a single-center retrospective study.低耗竭外周循环γδ T细胞作为预测非小细胞肺癌（NSCLC）患者化疗或靶向治疗临床获益率的生物标志物：一项单中心回顾性研究
BMC Cancer. 2025 Jan 30;25(1):178. doi: 10.1186/s12885-025-13497-2.
4
CMSS1: A RNA binding protein with pivotal roles in non-small cell lung cancer progression and prognosis.CMSS1：一种在非小细胞肺癌进展和预后中起关键作用的RNA结合蛋白。
BMC Cancer. 2025 Apr 14;25(1):688. doi: 10.1186/s12885-025-14044-9.
5
Comprehensive analysis pinpoints CCNA2 as a prognostic and immunological biomarker in non-small cell lung cancer.综合分析确定CCNA2是非小细胞肺癌的一种预后和免疫生物标志物。
BMC Pulm Med. 2025 Jan 11;25(1):14. doi: 10.1186/s12890-025-03490-7.
6
PD-L1 expression and T cells infiltration in patients with uncommon EGFR-mutant non-small cell lung cancer and the response to immunotherapy.罕见 EGFR 突变型非小细胞肺癌患者的 PD-L1 表达和 T 细胞浸润与免疫治疗反应。
Lung Cancer. 2020 Apr;142:98-105. doi: 10.1016/j.lungcan.2020.02.010. Epub 2020 Feb 19.
7
Prognostic characterization of immune molecular subtypes in non-small cell lung cancer to immunotherapy.免疫治疗中非小细胞肺癌免疫分子亚型的预后特征。
BMC Pulm Med. 2021 Nov 29;21(1):389. doi: 10.1186/s12890-021-01765-3.
8
The intratumoral distribution influences the prognostic impact of CD68- and CD204-positive macrophages in non-small cell lung cancer.肿瘤内分布影响 CD68 和 CD204 阳性巨噬细胞在非小细胞肺癌中的预后影响。
Lung Cancer. 2018 Sep;123:127-135. doi: 10.1016/j.lungcan.2018.07.015. Epub 2018 Jul 19.
9
Mitochondrial Pyruvate Carrier 1 as a Novel Prognostic Biomarker in Non-Small Cell Lung Cancer.线粒体丙酮酸载体 1 作为非小细胞肺癌的新型预后生物标志物。
Technol Cancer Res Treat. 2024 Jan-Dec;23:15330338241282080. doi: 10.1177/15330338241282080.
10
The role of Cancer-Testis antigens as predictive and prognostic markers in non-small cell lung cancer.癌症-睾丸抗原作为非小细胞肺癌预测和预后标志物的作用。
PLoS One. 2013 Jul 23;8(7):e67876. doi: 10.1371/journal.pone.0067876. Print 2013.

引用本文的文献

1
SEC61G Facilitates Brain Metastases via Antagonizing PGAM1 Ubiquitination and Immune Microenvironment Remodeling in Non-Small Cell Lung Cancer.SEC61G通过拮抗非小细胞肺癌中PGAM1的泛素化和免疫微环境重塑促进脑转移。
Int J Biol Sci. 2025 Jan 27;21(4):1436-1458. doi: 10.7150/ijbs.109187. eCollection 2025.

本文引用的文献

1
Role of cuproptosis-related gene in lung adenocarcinoma.铜死亡相关基因在肺腺癌中的作用。
Front Oncol. 2022 Dec 21;12:1080985. doi: 10.3389/fonc.2022.1080985. eCollection 2022.
2
Role of hippocampal circKcnk9 in visceral hypersensitivity and anxiety comorbidity of irritable bowel syndrome.海马体环状Kcnk9在肠易激综合征内脏高敏感性和焦虑共病中的作用。
Front Cell Neurosci. 2022 Nov 17;16:1010107. doi: 10.3389/fncel.2022.1010107. eCollection 2022.
3
Myeloid CD169/Siglec1: An immunoregulatory biomarker in viral disease.髓系CD169/唾液酸结合免疫球蛋白样凝集素1：病毒疾病中的一种免疫调节生物标志物。
Front Med (Lausanne). 2022 Sep 23;9:979373. doi: 10.3389/fmed.2022.979373. eCollection 2022.
4
Macrophages as tools and targets in cancer therapy.巨噬细胞作为癌症治疗的工具和靶点。
Nat Rev Drug Discov. 2022 Nov;21(11):799-820. doi: 10.1038/s41573-022-00520-5. Epub 2022 Aug 16.
5
Siglec Signaling in the Tumor Microenvironment.肿瘤微环境中的 Siglec 信号通路。
Front Immunol. 2021 Dec 13;12:790317. doi: 10.3389/fimmu.2021.790317. eCollection 2021.
6
E-Cadherin Expression and Blunted Interferon Response in Blastic Plasmacytoid Dendritic Cell Neoplasm.E-钙黏蛋白表达和幼稚浆细胞样树突状细胞瘤干扰素反应迟钝。
Am J Surg Pathol. 2021 Oct 1;45(10):1428-1438. doi: 10.1097/PAS.0000000000001747.
7
Activated natural killer cells predict poor clinical prognosis in high-risk B- and T-cell acute lymphoblastic leukemia.活化自然杀伤细胞预测高危 B 细胞和 T 细胞急性淋巴细胞白血病的不良临床预后。
Blood. 2021 Oct 21;138(16):1465-1480. doi: 10.1182/blood.2020009871.
8
Macrophage balance fraction determines the degree of immunosuppression and metastatic ability of breast cancer.巨噬细胞平衡分数决定乳腺癌的免疫抑制程度和转移能力。
Int Immunopharmacol. 2021 Aug;97:107682. doi: 10.1016/j.intimp.2021.107682. Epub 2021 Apr 23.
9
CD169 lymph node macrophages have protective functions in mouse breast cancer metastasis.CD169 淋巴结巨噬细胞在乳腺癌转移中具有保护作用。
Cell Rep. 2021 Apr 13;35(2):108993. doi: 10.1016/j.celrep.2021.108993.
10
CD169/SIGLEC1 is expressed on circulating monocytes in COVID-19 and expression levels are associated with disease severity.CD169/SIGLEC1在新冠病毒疾病（COVID-19）的循环单核细胞上表达，其表达水平与疾病严重程度相关。
Infection. 2021 Aug;49(4):757-762. doi: 10.1007/s15010-021-01606-9. Epub 2021 Apr 6.